The US Food and Drug Administration (FDA) is in crisis. What happens when the very agency tasked with ensuring public health is itself plagued by internal chaos? Just two weeks ago, the dramatic ousting of its top drug regulator sent shockwaves through the organization, exposing deep fractures and tensions within its leadership. This isn't just bureaucratic drama—it's a situation that could have far-reaching consequences for public trust and the safety of the drugs we rely on.
For an agency once revered for its stability and consistency, this turmoil is deeply unsettling. The latest twist came on Tuesday when the US Department of Health and Human Services (HHS) announced a surprising candidate to lead the Center for Drug Evaluation and Research (CDER). Richard Pazdur, a respected oncology expert and longtime FDA insider, was offered the role. But here's where it gets controversial: Pazdur reportedly turned down the position, according to Pink Sheet. Only then did top leaders scramble to find alternatives, leaving many to wonder: Why the hesitation? And what does this say about the state of the FDA?
This isn't an isolated incident. The FDA has been rocked by a series of upheavals. George Tidmarsh, appointed as CDER director in late July, resigned in early November amid accusations of retaliation against a former business partner and reports of internal strife. An explosive lawsuit alleged Tidmarsh used his position to harm his ex-partner. In the days leading up to his departure, Tidmarsh had also opposed a new rapid approval program, the “Commissioner’s National Priority Voucher,” questioning its legality. This program promised quicker drug reviews, but Tidmarsh’s concerns raise troubling questions about its implementation.
And this is the part most people miss: Tidmarsh reportedly clashed with Vinay Prasad, the agency’s chief medical and scientific officer and director of the Center for Biologics Evaluation and Research (CBER). Prasad allegedly bypassed Tidmarsh to assign tasks directly to CDER employees, further fueling tensions. While the HHS didn’t comment on these power struggles, they confirmed Tidmarsh’s departure. “Secretary Kennedy expects the highest ethical standards,” said press secretary Emily Hilliard, emphasizing a commitment to transparency.
Prasad’s own tenure has been tumultuous. Forced to resign in July, he returned less than a week later, reportedly due to FDA chief Marty Makary’s intervention. Peter Lurie, president of the Center for Science in the Public Interest and a former FDA associate commissioner, noted, “Prasad has obviously been very aggressive… but none of it speaks well to the kind of relations between center directors that are necessary to make the place work.”
The discord among top officials is “very unusual,” Lurie added. Even before Pazdur’s appointment, one CDER employee anonymously told The Guardian they’d never take the job, calling it a “career killer” amid the agency’s turmoil. “Plus, I’d have Vinay Prasad bitching at me or about me non-stop,” they added.
After Tidmarsh’s exit, several longtime employees expressed disinterest in the position. Sara Brenner, principal deputy commissioner at the FDA, even emailed CDER staff asking if anyone wanted to apply. Lurie called the appointment process “an enormous departure from accepted practices,” adding, “The degree of upheaval is really difficult to overestimate. It leaves people in the agency disconcerted.”
Opening the role to so many employees “reeks of desperation,” Lurie said, though he acknowledged Pazdur’s qualifications and the potential morale boost of an FDA insider. “There’s a sense among longtime employees that they’re under siege by outsiders who don’t understand how the FDA works,” he explained. “They’d be better served by someone who actually understands the institution.”
The pharmaceutical industry values stability at the FDA above all else. Public trust in the agency’s reviews is critical for maintaining safety and confidence. “Predictability is what they want,” Lurie said. “Otherwise, everything is in upheaval.” The FDA’s decades-long processes for evaluating drugs, biologics, and medical devices have been relatively uncontroversial—until now. “Suddenly, we have people who can get their drug reviewed in a one-day meeting,” Lurie noted.
Beyond disrupting regulatory work, the chaos could undermine the credibility of FDA experts, especially as attacks on scientific expertise persist. “If the assault on government continues,” Lurie warned, “the idea that the government is not to be trusted could actually become true.”
But here’s the real question: Can the FDA recover from this crisis, or is this the beginning of a deeper erosion of public trust? What do you think? Is the FDA’s turmoil a temporary setback, or a sign of systemic issues? Share your thoughts in the comments—this is a conversation we all need to have.
